Kinnate Biopharma Inc
KNTE
Get informed when a big investor buys or sells
+ FollowMarket Cap$124.99M
Close$
$1.16
56.4% downside
Current Fair Value
56.4% downsideOvervalued by 56.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $124.99 Million |
|---|---|
| Enterprise Value | $71.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.42 |
| Beta | 1.34 |
| Outstanding Shares | 47,124,349 |
Return
| Return on Equity | -69.63% |
|---|---|
| Return on Assets | -63.90% |
| Return on Invested Capital | -75.11% |
Valuation & Multiples
| P/E Ratio | -1.1 |
|---|---|
| PEG | 2.55 |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.59 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kinnate Biopharma Inc
31 employeesKinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for und...